Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration
Introduction: To assess whether switching from Ranibizumab to Aflibercept conferred benefit in visual acuity (VA) and central macular thickness (CMT) in patients with wet age-related macular degeneration (AMD). Methods: Mean change in VA and CMT was assessed in wet AMD patients 6 months prior and 6...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | Delhi Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.7869/djo.625 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849314226009538560 |
|---|---|
| author | Bhagya Weerasinghe Chandni Gupta Yasmin Levene Jai Shankar |
| author_facet | Bhagya Weerasinghe Chandni Gupta Yasmin Levene Jai Shankar |
| author_sort | Bhagya Weerasinghe |
| collection | DOAJ |
| description | Introduction:
To assess whether switching from Ranibizumab to Aflibercept conferred benefit in visual acuity (VA) and central macular thickness (CMT) in patients with wet age-related macular degeneration (AMD).
Methods:
Mean change in VA and CMT was assessed in wet AMD patients 6 months prior and 6 months after switch from Ranibizumab to Aflibercept, between July 2014 and November 2016.
Results:
90 eyes were switched from Ranibizumab to Aflibercept. VA improved in 11 eyes, 65 reported no change and 14 showed deterioration. Improvement in VA was not statistically significant (p>0.05). CMT improved in 24 eyes, 64 showed no change and in 2 there was deterioration. This improvement was statistically significant (p<0.01). Sub-analysis into patients that had switched to Aflibercept after 6 (28 patients) or >6 (62 patients) Ranibizumab injections showed no significant difference between these groups for VA or CMT change.
Conclusion:
Although there seemed to be an improvement in the CMT with Aflibercept, this did not translate as a statistical improvement in VA. Switching earlier to Aflibercept did not show any significant benefit in either VA or reduced CMT within the first 6 months. Our research however, requires extension as the benefits may be seen over a longer period of time. In conclusion, some patients with sub-optimal response to Ranibizumab may benefit from switching to Aflibercept. |
| format | Article |
| id | doaj-art-7b2b85c868e446cd8730a9dc3ca4c528 |
| institution | Kabale University |
| issn | 0972-0200 2454-2784 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Delhi Journal of Ophthalmology |
| spelling | doaj-art-7b2b85c868e446cd8730a9dc3ca4c5282025-08-20T03:52:32ZengWolters Kluwer Medknow PublicationsDelhi Journal of Ophthalmology0972-02002454-27842021-01-01313555810.7869/djo.625Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular DegenerationBhagya WeerasingheChandni GuptaYasmin LeveneJai ShankarIntroduction: To assess whether switching from Ranibizumab to Aflibercept conferred benefit in visual acuity (VA) and central macular thickness (CMT) in patients with wet age-related macular degeneration (AMD). Methods: Mean change in VA and CMT was assessed in wet AMD patients 6 months prior and 6 months after switch from Ranibizumab to Aflibercept, between July 2014 and November 2016. Results: 90 eyes were switched from Ranibizumab to Aflibercept. VA improved in 11 eyes, 65 reported no change and 14 showed deterioration. Improvement in VA was not statistically significant (p>0.05). CMT improved in 24 eyes, 64 showed no change and in 2 there was deterioration. This improvement was statistically significant (p<0.01). Sub-analysis into patients that had switched to Aflibercept after 6 (28 patients) or >6 (62 patients) Ranibizumab injections showed no significant difference between these groups for VA or CMT change. Conclusion: Although there seemed to be an improvement in the CMT with Aflibercept, this did not translate as a statistical improvement in VA. Switching earlier to Aflibercept did not show any significant benefit in either VA or reduced CMT within the first 6 months. Our research however, requires extension as the benefits may be seen over a longer period of time. In conclusion, some patients with sub-optimal response to Ranibizumab may benefit from switching to Aflibercept.https://journals.lww.com/10.7869/djo.625wet amdranibizumabafliberceptswitchoutcome |
| spellingShingle | Bhagya Weerasinghe Chandni Gupta Yasmin Levene Jai Shankar Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration Delhi Journal of Ophthalmology wet amd ranibizumab aflibercept switch outcome |
| title | Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration |
| title_full | Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration |
| title_fullStr | Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration |
| title_full_unstemmed | Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration |
| title_short | Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration |
| title_sort | clinical response to switch from ranibizumab to aflibercept in wet age related macular degeneration |
| topic | wet amd ranibizumab aflibercept switch outcome |
| url | https://journals.lww.com/10.7869/djo.625 |
| work_keys_str_mv | AT bhagyaweerasinghe clinicalresponsetoswitchfromranibizumabtoafliberceptinwetagerelatedmaculardegeneration AT chandnigupta clinicalresponsetoswitchfromranibizumabtoafliberceptinwetagerelatedmaculardegeneration AT yasminlevene clinicalresponsetoswitchfromranibizumabtoafliberceptinwetagerelatedmaculardegeneration AT jaishankar clinicalresponsetoswitchfromranibizumabtoafliberceptinwetagerelatedmaculardegeneration |